Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AMPENASDAQ:CALANASDAQ:CLVRNASDAQ:CMRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPEAmpio Pharmaceuticals$0.00-3.2%$0.00$0.00▼$0.45$3K3.9435 shs105 shsCALACalithera Biosciences$0.00$0.00$0.00▼$0.12$3K-2.3818,694 shsN/ACLVRClever Leaves$0.00$0.00$0.00▼$3.55$1K3571.181,913 shs15 shsCMRAComera Life Sciences$0.00$0.00▼$0.03$3K0.7710,614 shsN/A20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPEAmpio Pharmaceuticals0.00%0.00%+42.86%+42.86%-98.76%CALACalithera Biosciences0.00%0.00%-88.00%0.00%-97.00%CLVRClever Leaves0.00%0.00%+100.00%-66.67%-99.99%CMRAComera Life Sciences0.00%0.00%-50.00%-50.00%-99.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACLVRClever LeavesN/AN/AN/AN/AN/AN/AN/AN/ACMRAComera Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPEAmpio Pharmaceuticals 0.00N/AN/AN/ACALACalithera Biosciences 0.00N/AN/AN/ACLVRClever Leaves 0.00N/AN/AN/ACMRAComera Life Sciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPEAmpio PharmaceuticalsN/AN/AN/AN/A$4.04 per shareN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AN/ACLVRClever Leaves$17.42M0.00N/AN/A$14.02 per share0.00CMRAComera Life Sciences$1.00M0.00N/AN/AN/ANaNCompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPEAmpio Pharmaceuticals-$8.63M-$11.01N/A∞N/AN/AN/AN/AN/ACALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/ACLVRClever Leaves-$17.90M-$11.31N/A∞N/AN/AN/AN/A5/23/2025 (Estimated)CMRAComera Life Sciences-$18MN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/ACLVRClever LeavesN/AN/AN/AN/AN/ACMRAComera Life SciencesN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPEAmpio Pharmaceuticals5.73%CALACalithera BiosciencesN/ACLVRClever Leaves6.92%CMRAComera Life SciencesN/AInsider OwnershipCompanyInsider OwnershipAMPEAmpio Pharmaceuticals3.30%CALACalithera Biosciences6.60%CLVRClever Leaves8.20%CMRAComera Life Sciences8.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPEAmpio Pharmaceuticals201.14 million1.10 millionNo DataCALACalithera Biosciences604.87 million4.55 millionNot OptionableCLVRClever Leaves5601.76 million1.61 millionNo DataCMRAComera Life Sciences230.74 million28.00 millionNot OptionableCLVR, AMPE, CALA, and CMRA HeadlinesRecent News About These CompaniesTandy Leather Factory (NASDAQ:TLF) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comCarisma Therapeutics to Join Citizens JMP Life Sciences ConferenceMay 13, 2024 | msn.comComera Life Sciences Announces Sweeping Workforce TerminationJanuary 31, 2024 | msn.comComera Life Sciences Announces Bridge Financing and Exercise of Take Private OptionJanuary 4, 2024 | finance.yahoo.comComera Life Sciences Announces Bridge Financing and Exercise of Take Private OptionJanuary 4, 2024 | finance.yahoo.comComera Life Sciences to explore strategic alternativesDecember 6, 2023 | msn.comComera Life Sciences Announces Process Exploring Strategic AlternativesDecember 6, 2023 | finance.yahoo.comComera Life Sciences Stock (NASDAQ:CMRA), Analyst Ratings, Price Targets, PredictionsNovember 26, 2023 | benzinga.comComera Life Sciences Holdings Inc [CMRA] stock for 1,049,897 USD was acquired by Cherington CharlesNovember 18, 2023 | knoxdaily.comComera Life Sciences Designates Dorothy Clarke to Board of DirectorsNovember 14, 2023 | finance.yahoo.comComera Life Sciences Appoints Dorothy Clarke to Board of DirectorsNovember 13, 2023 | finance.yahoo.comComera Life Sciences GAAP EPS of -$0.10, revenue of $0.14MNovember 9, 2023 | msn.comComera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business HighlightsNovember 9, 2023 | finance.yahoo.comComera Life Sciences Holdings Inc [CMRA] Insider Activity: An Update for InvestorsNovember 8, 2023 | knoxdaily.comInvesting in Comera Life Sciences Holdings Inc (CMRA): What You Must KnowOctober 18, 2023 | knoxdaily.comComera Life Sciences Advancing Subcutaneous Monoclonal Antibody FormulationsOctober 18, 2023 | finance.yahoo.comComera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery ConferenceOctober 16, 2023 | finance.yahoo.comComera Life Sciences Holdings Inc [CMRA] 10% Owner makes an insider purchase of 2,053,789 shares worth 1.05 million.October 13, 2023 | knoxdaily.comMassive Insider Trade At Comera Life SciencesSeptember 13, 2023 | benzinga.com10% Owner At This Health Care Company Buys $1.05M of StockSeptember 12, 2023 | benzinga.comNew MarketBeat Followers Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains?By Chris Markoch | April 26, 2025View Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains?CLVR, AMPE, CALA, and CMRA Company DescriptionsAmpio Pharmaceuticals NYSE:AMPE$0.0030 0.00 (-3.23%) As of 05/22/2025 12:37 PM EasternAmpio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.Calithera Biosciences NASDAQ:CALA$0.0006 0.00 (0.00%) As of 05/22/2025Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Clever Leaves NASDAQ:CLVR$0.0004 0.00 (0.00%) As of 05/22/2025Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.Comera Life Sciences NASDAQ:CMRAComera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
